Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash & Equivalents (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Cash & Equivalents for 6 consecutive years, with $90.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 7.97% year-over-year to $90.9 million, compared with a TTM value of $90.9 million through Dec 2025, down 7.97%, and an annual FY2025 reading of $90.9 million, down 7.97% over the prior year.
  • Cash & Equivalents was $90.9 million for Q4 2025 at Cytek Biosciences, down from $93.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $376.8 million in Q3 2021 and bottomed at $75.5 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $206.4 million, with a median of $167.3 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 135.88% in 2021, then crashed 52.1% in 2023.
  • Year by year, Cash & Equivalents stood at $364.6 million in 2021, then dropped by 18.65% to $296.6 million in 2022, then plummeted by 43.59% to $167.3 million in 2023, then tumbled by 40.99% to $98.7 million in 2024, then decreased by 7.97% to $90.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for CTKB at $90.9 million in Q4 2025, $93.3 million in Q3 2025, and $75.5 million in Q2 2025.